Literature DB >> 9548907

Inclusion complexation of propofol with 2-hydroxypropyl-beta-cyclodextrin. Physicochemical, nuclear magnetic resonance spectroscopic studies, and anesthetic properties in rat. trapani@ippo.uniba.it.

G Trapani1, A Latrofa, M Franco, A Lopedota, E Sanna, G Liso.   

Abstract

An aqueous formulations of propofol 1 can be prepared by solubilizing it in the presence of 2-hydroxypropyl-beta-cyclodextrin (HP-beta-CD). This is potentially useful for parenteral administration of the drug. The aqueous solubility of 1 linearly increased as a function of HP-beta-CD concentration and showed features of an AL type diagram. Thermodynamic parameters were obtained by using the temperature dependence of the stability constant at temperatures of between 25 and 37 degrees C. The results indicate that complex formation is enthalpically, rather than entropically, driven and that it may involve van der Waals (dispersive) forces, rather than hydrophobic interactions. The structure of the inclusion complex propofol/HP-beta-CD was investigated in D2O, using 1H and 13C NMR spectroscopy. These studies revealed that the whole aromatic ring, as well as part of the isopropyl groups of the guest molecule, is located inside the HP-beta-CD cavity, while the hydroxy group is located at the rim of the wider cavity end. The geometrical features of the inclusion complex 1-HP-beta-CD are confirmed by 1D NOE difference spectra and molecular modeling experiments. The anesthetic activity in rat was investigated, and it was found that there are significant differences in induction time and sleeping time between 1 solubilized in the presence of HP-beta-CD and the formulation currently used (Diprivan), which is a 1% w/v oil/water emulsion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9548907     DOI: 10.1021/js970178s

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  9 in total

1.  Synthesis and evaluation of hydroponically alginate nanoparticles as novel carrier for intravenous delivery of propofol.

Authors:  Alireza Hassani Najafabadi; Saman Azodi-Deilami; Majid Abdouss; Hamid Payravand; Sina Farzaneh
Journal:  J Mater Sci Mater Med       Date:  2015-03-06       Impact factor: 3.896

2.  A novel, lipid-free nanodispersion formulation of propofol and its characterization.

Authors:  Hongming Chen; Zhong Zhang; Orn Almarsson; Jean-Francois Marier; Dina Berkovitz; Colin R Gardner
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

3.  Clotrimazole-cyclodextrin based approach for the management and treatment of Candidiasis - A formulation and chemistry-based evaluation.

Authors:  Noorullah Naqvi Mohammed; Pankaj Pandey; Nayaab S Khan; Khaled M Elokely; Haining Liu; Robert J Doerksen; Michael A Repka
Journal:  Pharm Dev Technol       Date:  2015-04-29       Impact factor: 3.133

4.  Design and evaluation of microemulsions for improved parenteral delivery of propofol.

Authors:  Abhijit A Date; Mangal S Nagarsenker
Journal:  AAPS PharmSciTech       Date:  2008-01-19       Impact factor: 3.246

5.  Intravenous formulation of N-hydroxy-N'-(4-n-butyl-2-methylphenyl)formamidine (HET0016) for inhibition of rat brain 20-hydroxyeicosatetraenoic acid formation.

Authors:  Ying Mu; Megan M Klamerus; Tricia M Miller; Lisa C Rohan; Steven H Graham; Samuel M Poloyac
Journal:  Drug Metab Dispos       Date:  2008-08-25       Impact factor: 3.922

6.  Preparation and evaluation of novel mixed micelles as nanocarriers for intravenous delivery of propofol.

Authors:  Xinru Li; Yanhui Zhang; Yating Fan; Yanxia Zhou; Xiaoning Wang; Chao Fan; Yan Liu; Qiang Zhang
Journal:  Nanoscale Res Lett       Date:  2011-03-31       Impact factor: 4.703

Review 7.  Novel propofol derivatives and implications for anesthesia practice.

Authors:  Aiden Y Feng; Alan D Kaye; Rachel J Kaye; Kumar Belani; Richard D Urman
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2017 Jan-Mar

8.  Physicochemical Characterization and Pharmacological Evaluation of Novel Propofol Micelles with Low-Lipid and Low-Free Propofol.

Authors:  Yongchao Chu; Tao Sun; Zichen Xie; Keyu Sun; Chen Jiang
Journal:  Pharmaceutics       Date:  2022-02-14       Impact factor: 6.321

9.  Monitored anesthesia care (MAC) sedation: clinical utility of fospropofol.

Authors:  Eric A Harris; David A Lubarsky; Keith A Candiotti
Journal:  Ther Clin Risk Manag       Date:  2009-12-29       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.